TAL1 and leukemia: The results of such studies areexpected to open up new possibilities for the development of highly effectivetherapeutic agents targeting TAL1-positive leukemia, which could act byinterfering with the protein-protein interactions between the components of theSCL complex but not affect the viability of normal hematopoietic cells[41].